At 90, Japanese bodybuilder Toshisuke Kanazawa has built an age-defying physique that is a testament to his rigorous training of two hours a day for six days a week. Kanazawa is still able to compete against athletes decades younger than him.

The 19-time national champion recently appeared at the International Fitness and Bodybuilding Federation (IFBB) World Fitness and Bodybuilding Championships in Santa Susanna, Spain, on October 30, 2026.

Although he did not finish on the podium, Kanazawa remains committed to bodybuilding and hopes to compete once more at 93.

“I like to try doing things that nobody else has done, and more than anything I want to pursue bodybuilding for the rest of my life,” he told Reuters.

In interviews with Reuters and The Guardian, Kanazawa has described how he has modified his exercise routine, diet and prioritised recovery to maintain muscle strength as he grows older.

Toshisuke Kanazawa Still Strength Trains For Two Hours A Day

Also read: Whey Protein For Muscle Gain: Do You Really Need 1.6 Grams Of Protein Per Kg?

Kanazawa trains for approximately two hours a day, six days a week, at his gym in Hiroshima, Japan. However, his routine has changed with age. He no longer performs heavy exercises, including squats and bench presses, and prefers using weight-training machines instead of free weights.

He said machines allow him to control movements and adjust resistance according to his physical capabilities. “I do what’s best for me and my body at this age,” he told The Guardian.

His approach speaks about the importance of recovery when it comes to strength training in older adults. It also reinforces that exercise needs to be adapted to changing strength, mobility and recovery capacity rather than maintaining the same intensity throughout life.

Kanazawa Prioritises Muscle Recovery

Kanazawa says recovery takes longer than it did when he was younger. “It takes longer to recover from weights sessions than it used to, so I make sure I rest properly between sets and get around seven hours’ sleep a night,” he told The Guardian.

Adequate recovery is important because resistance exercise creates stress on muscles, which need time to repair and adapt. Older adults may also experience age related stress when it comes to muscle recovery and the ability to build muscle.

Also read: Why Is Excess Belly Fat A Health Concern, Even In People Who Appear To Have A Normal Body Weight?

Kanazawa's Diet For Muscle Building

Kanazawa attributes his physical conditioning to a traditional Japanese diet that he has followed since turning 50. His regular meals include:

• Brown rice: A source of carbohydrates and dietary fibre.
• Natto: Fermented soybeans that provide plant-based protein.
• Miso soup: A traditional fermented soybean-based soup.
• Raw eggs: He has also described adding a couple of raw eggs to his miso soup.

“This is something I’ve been researching and want to learn more about. But ever since I turned 50, I’ve been building muscle by eating a purely Japanese diet which includes brown rice, natto, and miso soup,” he said.

He also revealed that he has reduced his protein shake intake with age. “I used to have six protein shakes a day but now I have three. As I get older, it’s harder to stomach that much liquid,” he said.

Kanazawa has also given up meat and fish and says he has never smoked or consumed alcohol.

Also read: Leading Gastroenterologist Padma Bhushan Dr S K Sarin Shares Dos & Don’ts For Healthy Liver At Times Health Summit 2026

He Adjusted His Training Instead Of Stopping

Kanazawa’s return to competitive bodybuilding at 50 came after he had retired from the sport in his mid-30s. He said he wanted to encourage his wife, who had a chronic illness, and realised that he had lost some of his own strength after retiring.

He eventually returned to competition and went on to win several masters championships. He believes older people should not automatically give up activities they enjoyed when they were younger.

“I worry that too many of them give up on the things they did when they were younger,” he said. He added, “I want to be a bodybuilder until the day I die.”

Strength Training Tips For Older Adults

Muscle mass and strength naturally decline with age due to a process called sarcopenia. This can affect mobility, balance and the ability to perform everyday activities.

The World Health Organization recommends that adults aged 65 and older undertake muscle strengthening exercises involving major muscle groups at least twice a week.

Older adults should also include varied physical activity that emphasises functional balance and strength on three or more days a week. Exercise intensity and type should be adjusted to individual health, fitness and mobility.

For years, body mass index (BMI) has been a key health marker to track obesity. But a recent study suggests that not everyone classified as obese based on their BMI may have obesity-related health problems. Researchers say just considering BMI alone may lead to incorrect diagnosis in some people while overlooking others with excess body fat and related health risks.

The international study, involving more than 844,000 adults across China, the UK, the US and Spain, supports a different approach that considers body fat distribution, waist measurement and the impact of excess fat on organ function.

Researchers propose distinguishing between two categories: pre-clinical obesity, in which excess body fat increases health risks but has not impaired organ function, and clinical obesity, in which excess fat is already affecting the body's ability to function.

BMI Alone Not Enough To Diagnose Obesity

Also read: Why WHO Wants To Use Smartwatches To Track Physical Activity & Sedentary Behaviour At A Population Level?

BMI is calculated by dividing a person's weight in kilograms by their height in metres squared. It is used to classify people as underweight, normal weight, overweight or obese.

However, BMI does not directly measure body fat or show where fat is distributed. It also cannot distinguish between fat and muscle mass. Consequently, two people with the same BMI may have very different body compositions and health risks.

The researchers found that adding waist circumference and waist-to-height ratio to BMI helped identify people whose excess body fat might otherwise be missed.

The analysis suggested that BMI alone missed obesity level body fat in up to 8.6% of participants, while incorrectly classifying up to 3.1% as having obesity in the study groups.

Professor Francesco Rubino, senior author of the study and Chair of Metabolic and Bariatric Surgery at King's College London, said, “Body mass index alone cannot tell us whether someone is already ill or at risk of illness, or what care they need, leaving people vulnerable to both undertreatment and overtreatment.”

Difference Between Clinical And Pre-Clinical Obesity

Also read: Loud Snoring Is Not Always Harmless: Sleep Apnoea can Become a Stroke-Risk Concern

The researchers used a framework proposed by the Lancet Diabetes and Endocrinology Commission in 2025. It separates obesity into two categories based on whether excess body fat has affected a person's health.

• Pre-clinical obesity: A person has excess body fat that increases their risk of developing health problems, but their organ function and everyday activities remain unaffected.

• Clinical obesity: Excess body fat has impaired organ function or affected a person's ability to perform daily activities. It is considered an active disease that requires clinical assessment.

The study estimated that only around 23% to 31% of people classified as having obesity across the four study populations had clinical obesity. This represented approximately 5.6% to 10.9% of the overall adult populations studied.

When Do People With Pre-Clinical Obesity Develop Health Problems?

The researchers followed participants over time to examine how often pre-clinical obesity progressed to clinical obesity.

They found that approximately 77% to 91% of people classified as having pre-clinical obesity did not progress to clinical obesity over 10 years. However, progression rates differed across the study populations.

Clinical obesity was linked with a higher risk of death while pre-clinical obesity had a more modest increase in risk.

Professor Rubino said, “Preclinical obesity should therefore be neither treated automatically as active disease nor dismissed as harmless. Some people may need preventive treatment, but its intensity should match their individual risk.”

The findings do not mean that people with pre-clinical obesity should ignore excess body fat. Rather, they highlight the importance of assessing individual health risks instead of making treatment decisions based on BMI alone.

People with excess body fat may still benefit from lifestyle hanges, treatment and preventive care even if they have not developed organ dysfunction.

Smartwatches and fitness trackers are widely used for counting daily steps and tracking workouts by millions. But the World Health Organization (WHO) is now seeking to task these wearables with bigger responsibilities. The global health body has issued proposals for wearable devices that could help countries measure physical activity and sedentary behaviour across populations.

In a notice published on November 8, WHO invited researchers, health authorities, technology developers and other stakeholders to review a draft Target Product Profile (TPP) for wearable devices worn on wrists. The aim is to ascertain what these devices should be capable of measuring before they are incorporated into national and subnational public health monitoring systems.

The proposal will remain open until December 6, 2026. WHO will use the feedback to revise and finalise the document and inform future implementation guidance.

WHO Want To Use Smartwatches For Public Health Monitoring

Also read: Lancet Study Says Obesity Drug Mazdutide Shows 18% Weight Loss In 32 Weeks: How Does It Compare To Wegovy?

Physical inactivity is a major risk factor for non-communicable diseases, including cardiovascular disease, type 2 diabetes and certain cancers. Sedentary behaviour, which involves spending prolonged periods sitting is also the cause of various adverse health outcomes.

Countries currently rely heavily on surveys to understand how physically active people are. However, these often depend on people reporting their own activity, which can lead to inaccurate data.

Wearable devices could provide a more objective way to collect information over a certain period of time. Instead of relying entirely on questionnaires, health authorities could use data from these devices to understand how much people move, how long they remain sedentary and how activity patterns vary across different population groups.

WHO says wearable technology could complement existing surveillance methods as countries work towards improving global physical activity targets.

WHO's Proposed Standards

Also read: Weight Loss Without Extreme Diets: What Sustainable Medical Weight Management Looks Like

The draft TPP outlines minimum specifications for smartwatches intended for population-level monitoring. It considers what makes a device suitable for collecting data across different populations.

The proposed framework covers:

• Measurement capabilities: What physical activity and sedentary behaviour indicators a device should be able to capture.
• Technical specifications: The minimum and additional features required for devices to be suitable for public health surveillance.
• Data access: How information can be retrieved, processed and used by health monitoring systems.
• Implementation: Practical considerations involved in deploying devices across communities and integrating them into existing surveillance programmes.
• Scalability and sustainability: Whether the technology can be used consistently across countries with different resources and technical capacities.

WHO is interested in feedback on whether the specifications proposed are practical and relevant to countries with limited resources.

Why Can't Countries Use Existing Smartwatches?

Although such wearables are widely available, their measurements are not interchangeable. Different manufacturers use different sensors, algorithms and methods to calculate steps, activity levels and sedentary time. As a result, two devices worn by the same person may produce different estimates.

A systematic review published in npj Digital Medicine in January 2026 examined 82 studies evaluating Apple Watch measurements across 14 health metrics. It found that measurement accuracy varied depending on the metric and testing conditions. While heart-rate measurements showed good overall agreement, step counts had moderate accuracy and energy expenditure data was inconsistent too.

This illustrates the need for standardisation. If countries use different devices and measurement methods, comparing physical activity data across populations becomes needlessly challenging.

WHO's proposed framework is intended to address these differences by identifying the device characteristics and protocols needed for consistent data collection.

Cost, access, privacy and digital literacy remain important challenges when it comes to implementing WHO's proposal. People without smartphones, reliable internet access or the ability to buy wearable devices could be underrepresented.

There are also questions about how personal movement data would be stored, shared and protected. Governments would need clear safeguards to ensure that participation is voluntary, data is handled responsibly and findings represent the wider population.

Mazdutide, an experimental weight-loss drug, could soon join the ever-expanding market of GLP-1 medications. The results from a recent clinical trial funded by Eli Lilly has found that mazdutide has shown an average reduction of 18.1% in body weight over 32 weeks. The trial was published in The Lancet Diabetes & Endocrinology.

The findings have drawn attention because the experimental drug produced significant weight loss in less than eight months, establishing its position among existing medicines like Wegovy.

However, the findings come from a phase 2 trial involving 179 participants. Its comparison with existing players like Wegovy are yet to be done formally.

What Did The Mazdutide Study Find?

Also read: Ozempic, Mounjaro Users Report Burning Skin Sensation: What Is Allodynia?

Published in November 2026, the randomised, double-blind, placebo-controlled trial evaluated mazdutide in 179 overweight or obese adults with overweight but without type 2 diabetes.

Participants, who were recruited from 24 centres in the United States, received the once-weekly injections of different doses of the drug or a placebo. At 32 weeks, the average weight changes were:

• Mazdutide 16 mg: 18.1% reduction in body weight
• Mazdutide 10 mg: 15.6% reduction
• Mazdutide 3–6 mg: 7.3% reduction
• Placebo: 0.9% reduction

The study also reported further weight reductions by week 48, suggesting that weight loss had not reached its maximum by the primary assessment.

However, tolerability of the drug drew attention too. Gastrointestinal problems, including nausea, vomiting and diarrhoea, were among the most common side effects.

Around 20% of participants receiving the highest 16 mg dose quit the treatment because of adverse events, primarily gastrointestinal disorders.

How Does Mazdutide Work?

Also read: Australia Approves First GLP-1 Weight Loss Pill: How It Works & Who Is Eligible

Mazdutide works differently from semaglutide, the active ingredient in Ozempic and Wegovy. It activates two hormone receptors involved in regulating appetite and metabolism: glucagon-like peptide-1 (GLP-1) and glucagon.

GLP-1 helps regulate blood sugar, which slows down emptying of the stomach and increases feelings of fullness, which can reduce food intake.

Glucagon is another hormone involved in regulating blood glucose and energy metabolism. By activating glucagon receptors along with GLP-1 receptors, mazdutide can affect energy expenditure and metabolism in addition to regulating appetite.

This dual action distinguishes it from semaglutide, which primarily targets the GLP-1 receptor.

Mazdutide Vs Wegovy

Also read: GLP-1 Drugs May Be More Effective Than Metformin At Preventing Diabetes: Study

Ozempic and Wegovy contain the same active ingredient, semaglutide, but have different approved uses and dosing.

Ozempic is primarily prescribed for type 2 diabetes and certain cardiovascular and kidney conditions, while Wegovy is approved for weight management.Here is how the trial results compare:

Mazdutide 16 mg showed 18.1% weight reduction in 32 weeks. Wegovy 2.4 mg showed 14.9% in 68 weeks.

In the STEP 1 trial, published in The New England Journal of Medicine in 2021, participants with overweight or obesity who received semaglutide 2.4 mg lost an average of 14.9% of their body weight over 68 weeks. Participants did not have diabetes.

Although mazdutide's 18.1% result seems higher than the 14.9% reported with Wegovy, the comparison has limitations. The trials differed in duration, participant characteristics, doses and study design. A direct head-to-head trial would be needed to establish which treatment produces greater weight loss.

Is Mazdutide A Promising Weight-Loss Drug?

Mazdutide has also been studied in China. In the phase 3 GLORY-2 trial, participants receiving 9 mg lost an average of 16.65% of their body weight over 60 weeks, compared to 1.50% in the placebo group.

Its recent findings are promising but it is too early to call mazdutide more effective than existing treatments. The US study was a relatively small phase 2 trial, and its highest dose led to a high rate of discontinuation due to adverse events. Larger phase 3 trials are important to establish its long-term effectiveness, safety and tolerability.